ABVC BioPharma, Inc.
ABVC
$0.911
$0.0354.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 69.11% | -11.98% | -62.57% | -83.63% | -68.79% |
| Total Other Revenue | 98.29% | -986.79% | -- | -- | -- |
| Total Revenue | 234.16% | -31.04% | -82.19% | -97.63% | -84.28% |
| Cost of Revenue | -99.74% | -67.30% | -58.64% | -29.77% | 5.45% |
| Gross Profit | 440.17% | 18.94% | -109.21% | -129.78% | -121.89% |
| SG&A Expenses | -9.35% | -30.21% | -22.21% | -17.71% | -57.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 197.92% | -267.59% | -- | -- | -- |
| Total Operating Expenses | -24.32% | -46.98% | -38.25% | -29.77% | -56.92% |
| Operating Income | 30.14% | 48.24% | 35.18% | 23.03% | 55.17% |
| Income Before Tax | 33.09% | 45.43% | 19.07% | 10.04% | 48.28% |
| Income Tax Expenses | -143.16% | -93.79% | -93.95% | -71.06% | -67.91% |
| Earnings from Continuing Operations | 36.49% | 49.61% | 25.36% | 14.50% | 49.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -27.74% | 405.93% | 506.74% | 460.85% | 544.77% |
| Net Income | 37.05% | 55.04% | 31.68% | 19.22% | 52.58% |
| EBIT | 30.14% | 48.24% | 35.18% | 23.03% | 55.17% |
| EBITDA | 30.32% | 48.40% | 35.29% | 23.07% | 55.29% |
| EPS Basic | 76.74% | 83.95% | 64.39% | 47.68% | 59.57% |
| Normalized Basic EPS | 75.84% | 85.25% | 64.02% | 47.29% | 60.36% |
| EPS Diluted | 76.51% | 83.76% | 64.31% | 47.64% | 59.53% |
| Normalized Diluted EPS | 75.84% | 85.25% | 64.02% | 47.29% | 60.36% |
| Average Basic Shares Outstanding | 169.00% | 187.16% | 141.18% | 82.86% | 36.99% |
| Average Diluted Shares Outstanding | 169.00% | 187.16% | 141.18% | 82.86% | 36.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |